Introduction:Basic information about 2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]ac, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid Basic information
| Product Name: | 2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid |
| Synonyms: | (+)-[(2s,6r)-6-[[(s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4-yl]acetic acid;2-[(2s)-6-[[(1s)-1-ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid;TEMOCAPRIL;(2E,5E)-2,6-bis(butylamino)-4-hepta-2,5-dienone;TEMOCAPRILDISCONTINUED SEE T017301;Temocapil;(2S,6R)-6-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic Aci;1,4-Thiazepine-4(5H)-acetic acid, 6-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-, (2S,6R)- (9CI) |
| CAS: | 111902-57-9 |
| MF: | C23H28N2O5S2 |
| MW: | 476.61 |
| EINECS: | |
| Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 111902-57-9.mol |
|
2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid Chemical Properties
| Melting point | 1680C |
| alpha | 23 +40° (c = 1.1 in DMF) |
| Boiling point | 717.4±60.0 °C(Predicted) |
| density | 1.33±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| pka | 3.73±0.10(Predicted) |
| form | Powder |
| color | Crystalline |
| CAS DataBase Reference | 111902-57-9(CAS DataBase Reference) |
Safety Information
2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid Usage And Synthesis
| Chemical Properties | Crystalline Powder |
| Uses | Angiotensin-converting enzyme (ACE) inhibitor. Hydrolyzed in vivo to the active diacid metabolite. |
| Definition | ChEBI: Temocapril is a dipeptide. |
| in vivo | Temocapril (10 mg/kg; p.o.; 21 d) enhances cardiomyocyte thioredoxin expression and ameliorates autoimmune myocarditis[3]. Temocapril (30 mg/kg; p.o.; daily; for 4 weeks) suppresses Angiotensin I-induced hypertension, plasma and renal ACE activity, but fails to reduce the level of Ang II in the kidney[4].
| Animal Model: | Experimental autoimmune myocarditis (EAM) rat model[3] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; administration by water; 21 days | | Result: | Ameliorated EAM and prevented cellular proteins from oxidation. Enhanced cardiomyocyte redox regulatory protein TRX expression.| Animal Model: | Male Sprague Dawley rats[4] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage, daily, for 4 weeks | | Result: | Suppressed the blood pressure elevation induced by Ang I. |
| 2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid Preparation Products And Raw materials |